B
Bullisch
Bullisch · 25%BTAI
$0.94
Szenariopreis
$0.074
-0.027 (-37.11%)Zum Schluss
Loading chart…
- Hoch
- 0.094
- Eröffnung
- 0.093
- Volumengewichteter Durchschnittskurs
- 0.08
- Volumen
- 47.48M
- Marktkap.
- 47.66M
- Tief
- 0.069
- Umsatz
- 3.74M
- EV/EBITDA, TTM
- -0.08
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
KI-Analyse of BioXcel Therapeutics Inc (BTAI)
VerkaufenBioXcel Therapeutics Inc is not a good buy right now due to its significant financial distress and recent bankruptcy filing. The current price is $0.0739, which reflects a staggering 95.65% decline year-to-date. Additionally, the company has reported a gross margin of only 87.91% in the most recent quarter, indicating severe operational challenges. The primary risk is its recent bankruptcy filing, which raises concerns about the company's ability to continue operations and meet obligations.
Analystenbewertungen (4)
+7342.49% Aufwärtspotenzial
Kaufen
4 Kaufen
0 Halten
0 Verkaufen
Aktuell: 0.07
Tief
1.00
Durchschnitt
5.50
Hoch
10.00
H.C. Wainwright
Kaufen
$5
2026-04-02
H.C. Wainwright
2026-04-02
Kursziel
$5
Kaufen
Rodman & Renshaw
Kaufen
$17
2026-03-17
Rodman & Renshaw
2026-03-17
Kursziel
$17
Kaufen
H.C. Wainwright
Kaufen
$6
2026-03-05
H.C. Wainwright
2026-03-05
Kursziel
$6
Kaufen
Mizuho
Neutral
$4
2025-09-12
Mizuho
2025-09-12
Kursziel
$4
Neutral
H.C. Wainwright
Kaufen
$10
2025-08-15
H.C. Wainwright
2025-08-15
Kursziel
$10
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von BioXcel Therapeutics Inc (BTAI) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -1.74.
Alphio-AI-Kursszenarien für BTAI
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die BTAI halten
Event-Zeitleiste
News
2.009-12Yahoo FinanceTeva Agrees to $125 Million Acquisition of BioXcel Assets
9.008-31NASDAQ.COMBioXcel Therapeutics Signs Asset Sale Agreement with Teva Pharmaceuticals
9.008-28NASDAQ.COMBioXcel Therapeutics Sells Assets and Files for Bankruptcy
9.008-28NewsfilterBioXcel Therapeutics Initiates Asset Sale Process Under Bankruptcy
8.508-13CNBCGIFT City in India Attracts Global Asset Management Firms
BTAI FAQ – beantwortet von Alphio AI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
BioXcel Therapeutics Inc is not a good buy right now due to its significant financial distress and recent bankruptcy filing. The current price is $0.0739, which reflects a staggering 95.65% decline year-to-date. Additionally, the company has reported a gross margin of only 87.91% in the most recent quarter, indicating severe operational challenges. The primary risk is its recent bankruptcy filing, which raises concerns about the company's ability to continue operations and meet obligations.
4 analysts cover BTAI: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.50.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
- Bitcoin Bear Market 2026: Why BTC Fell Below $70K and How Investors Can Manage Crypto RiskBitcoin is about 45% below its $126K peak as Fed hikes, 5% yields and ETF outflows bite. See how the 2026 bear market compares and how to manage crypto risk.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.